2021
DOI: 10.1016/j.tmaid.2021.101983
|View full text |Cite
|
Sign up to set email alerts
|

Evolution of SARS-CoV-2: A prediction on the lineages and vaccine effectiveness

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3
1
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 4 publications
0
4
0
Order By: Relevance
“…Adopting mass vaccination against COVID-19 vaccine has become a key measure for countries to fight against the epidemic 43 . In addition, the development and approval of intra-nasal vaccines against COVID-19 have turned out to be a global game changer 44 .…”
Section: Discussionmentioning
confidence: 99%
“…Adopting mass vaccination against COVID-19 vaccine has become a key measure for countries to fight against the epidemic 43 . In addition, the development and approval of intra-nasal vaccines against COVID-19 have turned out to be a global game changer 44 .…”
Section: Discussionmentioning
confidence: 99%
“…As of March 2021, >132 million COVID‐19 cases with 2.86 million deaths have been reported worldwide 3 . New variants have alarming implications on the efficiency of current vaccines, 41 signaling a pandemic that is far from over. Heath care personnel will continue to remain on the frontlines and therefore require respirator use.…”
Section: Discussionmentioning
confidence: 99%
“…Due to the limited understanding of the COVID-19 transmission and infectivity up to now, there are still no effective mitigation measures 6 . Despite of considerable efforts in vaccine development 7 10 , prevention 11 14 , and advancements in digital health 15 , 16 , the COVID-19 pandemic has a significant impact on healthcare systems and vulnerable patients, especially those with malignant brain tumours 4 , 17 . Glioblastoma (GBM) is the most common malignant primary intracranial lesion, accounting for nearly half of all primary malignant central nervous system tumours.…”
Section: Introductionmentioning
confidence: 99%